Professional Documents
Culture Documents
S2 2013 323118 Bibliography PDF
S2 2013 323118 Bibliography PDF
Ayalew, K., Sumati, N., Yuliya, Y. and Barbara, AJ. 2003, Carbapenems in
Pediatrics, J Ther Drug Monit, 25(5) : 593-599.
BNF staff. 2011, British National Formulary 61, Pharmaceutical Press, London,
UK, p. 346.
BNFC org. 2009, British National Formulary for children, BMJ Publishing Group
Ltd., London, UK, p. 327.
Brunton, L., Lazo, JS. and Parker, KL. (ed). 2006, Goodman & Gilman’s The
Pharmacological Basis of Therapeutics, 11th Edition, The McGraw-Hill
Comp., chapter 42.
Centre for Disease Control and Prevention, 2011a, ‘Delivering safe care for
patients : all healthcare providers play a role’, Get Smart Programs, diakses
pada 29 September 2012 <http://www.cdc.gov/getsmart/healthcare/>
58
Dedic, M., Tomanovic, S. and Nikolic, L. 2005, ‘Sensitivity to meropenem and
imipenem pseudomonas strains isolated from various patients material’,
Abstract number : 1135_20 presented to 15th European Congress of
Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark,
April 2-5.
Dipiro, J.T., Talbert, H.L., Yee, G.C. Matzke, G.R., Wells, B.G. and Posey, L.M.
2011, Pharmacotherapy a Pathophysiologic Approach, 8th ed, The
McGraw-Hill companies, New York, USA, chapter 116.
Edwards, SJ., Emmas, CE. and Campbell, HE. 2005, Systematic review
comparing meropenem with imipenem plus cilastatin in the treatment of
severe infection, Curr Med Res Opin, 21(5) : 785-794.
Gyssens, IC., Van de Brook, PJ., Kullberg, BJ. and van der Meer, JW. 1992,
Optimizing Antimicrobial Therapy, J Antimicrob Chemother, 30 : 724-727.
Hadi, U., Duerink, DO., Lestari, ES., Nagelke, NJ., Keuter, M., Veld, DH., et al.
2008, Audit of antibiotic prescribing in two governmental teaching hospitals
in Indonesia, Clin Microb Infect, 14(7) : 698-707.
59
Hong, T., Molland, ES., Abdalhamid, B., Hanson, ND., Wang, J., Sloan, C. et al.
2005, Escherichia coli : Development of carbapenem resistance during
therapy, Clin Infect Dis, 40 : 84-86.
Hughes, WT., Armstrong, D., Bodey, GP. 2002, Guideline for the use of
antimicrobial agents in neutropenic patients with cancer, Clin Infect Dis, 34
: 730-751.
Kaushal, R., Bates, DW., Abramson, EL., Soukup, JR., and Goldmann, DA. 2008,
Unit-based clinical pharmacists’ prevention of serious medication errors in
pedatric inpatient, Am J Health-Syst Pharm, 65 : 1254-1260.
Lacy, CF., Armstrong, LL. Goldman, MP. and Lance, LL. (ed). 2009, Drug
Information Handbook, 18th Edition, Lexi-Comp Inc., USA, p. 1079.
MacLaren, R., Bond, CA., Martin, SJ., Fike D. 2008, Clinical and Economic
Outcomes of Involving Pharmacist in The Direct Care of Critically Ill
Patients with Infections, Crit Care Med, 36(12) : 3269-70.
Odio, CM., Puig, JR. and Feris, JM. 1999, Prospective, randomized, investigator-
blinded studyof the efficacy and safety of meropenem vs. Cefotaxime
60
therapy in bacterial meningitis in children. Meropenem Meningitis Study
Group, Pediatr Infect Dis J, 18(7) : 581-590.
Sari, A., 2010. ‘Pengaruh Pelayanan Informasi Obat Terhadap Potensi Interaksi
Obat Pada Pasien Rawat Inap Penyakit Dalam di RSUD Prof. Dr. Margono
Soekarjo Purwokerto Periode Mei-Agustus 2010’, Tesis, M.Sc., Universitas
Gadjah Mada, Yogyakarta.
Sugiyono, 2012, Statistik untuk Penelitian, Alfabeta, Bandung, hal. 143, 376.
61
Thawani, V., Gharpure, K. And Paranjpe, BD. 2006, Antibiotics :
Pharmacoepidemiology of antibiotics, our experience, Regional Health
Forum WHO South-East Asia Region, 2(2) : 1343.
Tunkel, AR., Hartman, BJ., Kaplan, SL. 2004, Practice guideline for the
management of bacterial meningitis in children. Clin Infect Dis, 39 : 1267-
1284.
Wolter, DJ., Acquazzino, D., Goering, RV., Sammut, P., Khalat, N. And Hanson,
ND. 2008, Emergence of carbapenem resistance in Pseudomonas
aeruginosa isolate from a patient with cystic fibrosis in the absence of
carbapenem therapy, CID, 48 : 137-141.
World Health Organization, 1985, The Conference of Experts on the Rational Use
of Drugs, Nairobi, WHO, p. 35.
62